Syros Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Syros Pharmaceuticals
SYRS Stock  USD 0.13  0.04  51.52%   
Syros Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Syros Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Syros Pharmaceuticals financial statements helps investors assess Syros Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Syros Pharmaceuticals' valuation are summarized below:
Gross Profit
-88.3 M
Market Capitalization
2.3 M
Enterprise Value Revenue
11.0187
Revenue
386 K
Earnings Share
(3.07)
There are over one hundred nineteen available fundamental trend indicators for Syros Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should double-check Syros Pharmaceuticals' current fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 141.1 M in 2025. Enterprise Value is likely to drop to about 99.6 M in 2025

Syros Pharmaceuticals Total Revenue

7.61 Million

Check Syros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syros Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 6.2 M or Selling General Administrative of 18.9 M, as well as many indicators such as Price To Sales Ratio of 24.26, Dividend Yield of 0.0 or PTB Ratio of 12.51. Syros financial statements analysis is a perfect complement when working with Syros Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Syros Pharmaceuticals Correlation against competitors.
For more information on how to buy Syros Stock please use our How to Invest in Syros Pharmaceuticals guide.

Syros Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets147.5 M193.4 M120.5 M
Slightly volatile
Other Current Liabilities11 M18.6 M8.1 M
Slightly volatile
Total Current Liabilities22.2 M42.2 M17 M
Slightly volatile
Total Stockholder Equity18.2 M19.2 M62.3 M
Pretty Stable
Other Liabilities29.5 M28.1 M10.9 M
Slightly volatile
Property Plant And Equipment Net16.6 M22.4 M12.1 M
Slightly volatile
Accounts Payable13.9 M13.3 M4.7 M
Slightly volatile
Cash93.7 M160.5 M84.2 M
Slightly volatile
Non Current Assets Total21.7 M26.7 M15.6 M
Slightly volatile
Non Currrent Assets Other2.6 M4.3 M1.9 M
Slightly volatile
Other Assets5.4 M9.7 M4.3 M
Slightly volatile
Long Term Debt21.4 M39.7 M18.5 M
Slightly volatile
Cash And Short Term Investments119.8 M160.5 M100.7 M
Slightly volatile
Net Receivables1.4 M1.5 M4.9 M
Pretty Stable
Common Stock Total Equity28.2 K23 K18.8 K
Slightly volatile
Common Stock Shares Outstanding34.2 M32.6 M8.2 M
Slightly volatile
Liabilities And Stockholders Equity147.5 M193.4 M120.5 M
Slightly volatile
Non Current Liabilities Total138.7 M132.1 M43.2 M
Slightly volatile
Other Current Assets6.6 M6.3 M2.4 M
Slightly volatile
Other Stockholder Equity892.9 M850.4 M323.9 M
Slightly volatile
Total Liabilities183 M174.2 M61.5 M
Slightly volatile
Deferred Long Term Liabilities953.1 K1.5 M1.4 M
Very volatile
Property Plant And Equipment Gross19.9 M31.2 M14.7 M
Slightly volatile
Short and Long Term Debt8.1 M7.7 M3.6 M
Slightly volatile
Total Current Assets125.8 M166.7 M104.9 M
Slightly volatile
Short Term Debt10.9 M10.3 M2.8 M
Slightly volatile
Common Stock32.1 K29.9 K22.4 K
Slightly volatile
Property Plant Equipment12.6 M13.1 M9 M
Slightly volatile
Short and Long Term Debt Total75 M71.4 M27 M
Slightly volatile
Long Term Debt Total49.1 M46.7 M16.2 M
Slightly volatile
Capital Surpluse828.2 M788.7 M327.9 M
Slightly volatile
Current Deferred Revenue6.4 M5 M3.5 M
Slightly volatile
Capital Lease Obligations16.7 M24 M10.2 M
Slightly volatile
Net Invested Capital110.8 M66.6 M83.7 M
Slightly volatile
Net Working Capital122.2 M124.5 M90.6 M
Slightly volatile
Capital Stock32 K23.4 K35.5 K
Very volatile
Non Current Liabilities Other74.6 M71 M28.2 M
Slightly volatile

Syros Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.1 M2.6 M1.6 M
Slightly volatile
Selling General Administrative18.9 M32.5 M14.6 M
Slightly volatile
Other Operating Expenses87.4 M159.8 M68.4 M
Slightly volatile
Research Development68.1 M124.4 M53.5 M
Slightly volatile
Total Operating Expenses87.4 M159.8 M68.4 M
Slightly volatile
Preferred Stock And Other Adjustments2.9 M3.3 M3.6 M
Slightly volatile
Non Operating Income Net Other54.8 M52.2 M15.6 M
Slightly volatile
Reconciled Depreciation2.7 M2.6 M2.1 M
Slightly volatile
Interest Income8.2 M7.8 M1.9 M
Slightly volatile

Syros Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.3 M12 M5.9 M
Slightly volatile
Begin Period Cash Flow205.9 M196.1 M71.2 M
Slightly volatile
Depreciation1.9 M2.6 M1.5 M
Slightly volatile
Capital Expenditures297.2 K312.8 K1.8 M
Very volatile
End Period Cash Flow87.1 M162.9 M70.8 M
Slightly volatile
Issuance Of Capital Stock86.2 M49.8 M72.1 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio24.2625.54119
Slightly volatile
PTB Ratio12.5111.924.9725
Slightly volatile
Days Sales Outstanding45.447.791.2 K
Pretty Stable
Book Value Per Share0.640.6844.0938
Slightly volatile
Stock Based Compensation To Revenue1.151.215.7559
Slightly volatile
Capex To Depreciation0.130.142.0987
Slightly volatile
PB Ratio12.5111.924.9725
Slightly volatile
Days Of Inventory On Hand1.0E-41.0E-41.0E-4
Slightly volatile
Payables Turnover0.290.180.3146
Slightly volatile
Sales General And Administrative To Revenue3.113.2711.6481
Slightly volatile
Average Inventory0.550.5727.2 K
Pretty Stable
Research And Ddevelopement To Revenue11.8912.5245.3316
Slightly volatile
Capex To Revenue0.02990.03152.3642
Slightly volatile
Cash Per Share5.385.6647.8604
Slightly volatile
Days Payables Outstanding1.7 K2.2 K1.8 K
Slightly volatile
Income Quality0.690.60.8248
Very volatile
Net Debt To EBITDA0.540.570.9361
Pretty Stable
Current Ratio4.324.557.832
Pretty Stable
Tangible Book Value Per Share0.640.6844.0938
Slightly volatile
Receivables Turnover8.37.913.187
Slightly volatile
Shareholders Equity Per Share0.640.6844.0071
Slightly volatile
Debt To Equity3.523.350.8113
Slightly volatile
Capex Per Share0.01050.0112.7732
Slightly volatile
Revenue Per Share0.30.321.1668
Very volatile
Interest Debt Per Share3.72.143.3908
Slightly volatile
Debt To Assets0.350.330.1374
Slightly volatile
Operating Cycle45.447.791.2 K
Pretty Stable
Price Book Value Ratio12.5111.924.9725
Slightly volatile
Days Of Payables Outstanding1.7 K2.2 K1.8 K
Slightly volatile
Ebt Per Ebit1.081.471.0219
Slightly volatile
Company Equity Multiplier9.549.082.9983
Slightly volatile
Long Term Debt To Capitalization0.310.610.3438
Slightly volatile
Total Debt To Capitalization0.750.710.2341
Slightly volatile
Debt Equity Ratio3.523.350.8113
Slightly volatile
Quick Ratio4.324.557.8313
Pretty Stable
Net Income Per E B T1.00.60.9444
Slightly volatile
Cash Ratio4.164.376.8298
Pretty Stable
Days Of Inventory Outstanding1.0E-41.0E-41.0E-4
Slightly volatile
Days Of Sales Outstanding45.447.791.2 K
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.161.151.0793
Very volatile
Price To Book Ratio12.5111.924.9725
Slightly volatile
Fixed Asset Turnover0.310.460.2867
Slightly volatile
Debt Ratio0.350.330.1374
Slightly volatile
Price Sales Ratio24.2625.54119
Slightly volatile
Asset Turnover0.03340.05320.0312
Slightly volatile
Price Fair Value12.5111.924.9725
Slightly volatile

Syros Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap141.1 M198.6 M146.3 M
Slightly volatile

Syros Fundamental Market Drivers

Cash And Short Term Investments139.5 M

Syros Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Syros Pharmaceuticals Financial Statements

Syros Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Syros Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Syros Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Syros Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5 M6.4 M
Total Revenue11.4 M7.6 M
Cost Of Revenue2 M1.9 M
Stock Based Compensation To Revenue 1.21  1.15 
Sales General And Administrative To Revenue 3.27  3.11 
Research And Ddevelopement To Revenue 12.52  11.89 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.32  0.30 
Ebit Per Revenue(11.68)(12.27)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Syros Stock Analysis

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY